Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotine patch + nicotine lozenge (University of Wisconsin-Madison)
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Small Molecules
- Administration
- Transdermal, Oral
01
Overview
nicotine patch + nicotine lozenge is a combination nicotine replacement therapy (NRT) regimen developed and evaluated by the University of Wisconsin-Madison Center for Tobacco Research and Intervention (UW-CTRI). The therapy utilizes a long-acting transdermal nicotine patch to provide steady-state nicotine levels, supplemented by short-acting nicotine lozenges (typically 2 mg or 4 mg) used on an as-needed basis to address breakthrough cravings and acute withdrawal symptoms. Nicotine serves as an agonist at nicotinic acetylcholine receptors (nAChRs) in the brain, substituting for the nicotine previously obtained through tobacco use. This combination approach has been shown in Phase 4 clinical trials to be more effective than nicotine monotherapies for achieving long-term tobacco abstinence.
- Brand names
- NicodermCommit
- Other names
- patch + lozengecombination nicotine replacement therapycNRTnicotine patch plus nicotine lozenge
02
Targets
α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)
Beyond the preview
Go deeper on nicotine patch + nicotine lozenge (University of Wisconsin-Madison).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotine patch + nicotine lozenge (University of Wisconsin-Madison).